• Explore /
  • Poster
  • / Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).

Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).

Abstract Poster

Authors

Matthias Holdhoff

Matthias Holdhoff

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Matthias Holdhoff , Xiaobu Ye , Roy E. Strowd , Louis B. Nabors , Tobias Walbert , Frank S. Lieberman , Stephen Joseph Bagley , John B. Fiveash , Joy D. Fisher , Serena Desideri , Marc Engelhardt , Thomas Kaindl , Heidi A Lane , Stuart A. Grossman , Lawrence Kleinberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

NCT03250299

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2058)

DOI

10.1200/JCO.2023.41.16_suppl.2058

Abstract #

2058

Poster Bd #

415

Abstract Disclosures

Similar Posters

First Author: Louis B. Nabors

First Author: Louis B. Nabors

First Author: Warren P. Mason

First Author: Jiayi Huang